Full Year 2023 Investor Presentation

4 Investor presentation Full year 2023 Novo NordiskⓇ Strategic Aspirations 2025 | Highlights full year 2023 Purpose and sustainability (ESG) Progress towards zero environmental impact Carbon emissions decreased by 34% vs 20191 Adding value to society Medical treatment to 40.5 million people with diabetes Reached more than 52,000 children in Changing Diabetes in Children programme Partnership with Aspen to produce human insulin for Africa Being recognised as a sustainable employer Share of women in senior leadership positions has increased to 41% from 39% in 2022 IIIIIO Innovation and therapeutic focus . · . Light blue indicates developments in Q4 2023 Further raise innovation bar for Diabetes treatment FLOW stopped for efficacy based on interim analysis Successful completion of phase 3 trial with IcoSema Develop superior treatment solutions for obesity Successful completion of SELECT CVOT Acquisition of Inversago Pharma Successful completion of phase 1 trial with oral amycretin Strengthen and progress Rare Disease pipeline . Somapacitan approved in the US, EU and Japan Establish presence in CV & Emerging Therapy Areas Phase 1 trial initiation with VAP-1i in MASH ピ Commercial execution Diabetes value market share increased by 1.9%-points to 33.8%2 Obesity care sales of DKK 41.6 billion (+154% at CER) Rare disease sales of DKK 17.2 billion (-15% at CER) Financials Sales growth of 36% (CER) and operating profit growth of 44% (CER) Operational leverage reflecting sales growth Free cash flow of DKK 68.3 billion and DKK 61.7 billion returned to shareholders 1Scope 1,2 and partial scope 3 limited to CO2 emissions from business flights and product distribution. Carbon emissions decreased by 8% in 2023 compared to 2022; 2MAT (Moving annual total) value market share CER: Constant exchange rates; CV: Cardiovascular; CVOT: Cardiovascular outcomes trial Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth

View entire presentation